Related Experiment Video
Updated: May 27, 2026
05:16
Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
Published on: August 4, 2021
Recurrent pregnancy loss: TNF-α and IL-10 polymorphisms
1Centre for Genetic Disorders, Guru Nanak Dev University, Amritsar, India.
Journal of Human Reproductive Sciences
|November 9, 2011
Summary
This study found no association between specific interleukin-10 (IL-10) and tumor necrosis factor-alpha (TNF-α) gene polymorphisms and recurrent pregnancy loss in the studied group. Further research with larger, diverse populations is needed to confirm these findings.
Area of Science:
- Reproductive Immunology
- Human Genetics
- Obstetrics and Gynecology
Background:
- Recurrent pregnancy loss (RPL) necessitates evaluation of genetic, anatomical, endocrine, infectious, and immunological factors.
- Cytokine gene polymorphisms, specifically in tumor necrosis factor-alpha (TNF-α) and interleukin-10 (IL-10) promoter regions, have been implicated in RPL.
Purpose of the Study:
- To investigate the association between IL-10 -592C/A and TNF-α -308 G/A promoter polymorphisms and recurrent miscarriages.
- To determine if these specific genetic variations contribute to pregnancy loss in women with a history of at least three consecutive miscarriages.
Main Methods:
- Genotyping analysis was performed on 50 women diagnosed with RPL.
- The study compared these cases with a control group of 50 healthy women with two or more children.
- IL-10 -592C/A and TNF-α -308G/A promoter polymorphisms were assessed for their association with pregnancy loss.
Main Results:
- The study found no statistically significant association between IL-10 -592C/A promoter polymorphisms and recurrent miscarriages.
- Similarly, no association was detected between TNF-α -308 G/A promoter polymorphisms and recurrent pregnancy loss in the investigated cohort.
Conclusions:
- The current findings suggest that the investigated IL-10 and TNF-α promoter polymorphisms may not be significant risk factors for recurrent pregnancy loss in this population.
- Larger sample sizes and diverse ethnic groups are required to definitively establish or refute the role of these genetic markers in RPL.
- Further research could aid in the personalized management of immunologically mediated recurrent miscarriages.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...